Nautilus Biotechnology, Inc. (NAUT) News

Nautilus Biotechnology, Inc. (NAUT): $2.94

0.12 (+4.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NAUT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter NAUT News Items

NAUT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NAUT News Highlights

  • For NAUT, its 30 day story count is now at 5.
  • Over the past 28 days, the trend for NAUT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about NAUT are DECK and III.

Latest NAUT News From Around the Web

Below are the latest news stories about Nautilus Biotechnology Inc that investors may wish to consider to help them evaluate NAUT as an investment opportunity.

Nautilus Biotechnology, Inc. 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Nautilus Biotechnology, Inc. in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 24, 2022

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial Results

SEATTLE, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021. Fiscal Year 2021 Highlights In June, completed a business combination transaction with ARYA Sciences Acquisition Corp III and became a publicly traded company, with gross proceeds from this transaction totaling approximately $345.5 m

Yahoo | February 24, 2022

Nautilus to Participate in the 42nd Annual Cowen Health Care Conference

SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating virtually in the upcoming 42nd Annual Cowen Health Care Conference. Nautilus’ management is scheduled to present on Monday, March 7th at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the

Yahoo | February 16, 2022

Clarius Group, LLC Buys BTC BlackRock Ultra Short-Term Bond ETF, , Vanguard Ultra-Short Bond ...

Investment company Clarius Group, LLC (Current Portfolio) buys BTC BlackRock Ultra Short-Term Bond ETF, , Vanguard Ultra-Short Bond ETF, Vanguard FTSE Emerging Markets ETF, iShares Core U.S.

Yahoo | February 2, 2022

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the fourth quarter and full year 2021 before market open on Thursday, February 24th, 2022. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, bus

Yahoo | January 27, 2022

A look at insider stock sales among Portland-area companies in 2021 (Photos)

New tax rules in Washington state have led many public company executives to examine their holdings.

Yahoo | December 16, 2021

Insider Buying: The Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Co-Founder Just Bought 1.5% More Shares

Nautilus Biotechnology, Inc. ( NASDAQ:NAUT ) shareholders (or potential shareholders) will be happy to see that the...

Yahoo | December 5, 2021

Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome

Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a strategic development and supply partnership.

Yahoo | November 2, 2021

Nautilus Biotechnology Reports Third Quarter 2021 Financial Results

SEATTLE, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today reported financial results for the third quarter ended September 30, 2021. Recent Highlights Initiated a strategic partnership with Abcam, a world leader in the design and production of commercial antibodies, which we expect to accelerate our technology development pipeline and provide access to

Yahoo | November 2, 2021

Nautilus Biotechnology to Announce Third Quarter of Fiscal Year 2021 Financial Results on November 2, 2021

SEATTLE, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter of fiscal year 2021 before market open on Tuesday, November 2nd, 2021. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, busin

Yahoo | October 11, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5745 seconds.